Literature DB >> 7718896

Functional asplenia in hemoglobin SC disease.

P A Lane1, J L O'Connell, J L Lear, Z R Rogers, G M Woods, K L Hassell, D L Wethers, D W Luckey, G R Buchanan.   

Abstract

The incidence of functional asplenia in sickle-hemoglobin C (SC) disease has not been defined, and the use of prophylactic penicillin to prevent life-threatening septicemia in this disorder is controversial. The percentage of red blood cells with pits (pit count) is a reliable assay of splenic function in other disorders but has not been validated in hemoglobin SC disease. To address these issues, we conducted a prospective, multicenter study of splenic function in persons with hemoglobin SC disease. Baseline clinical data were recorded, and red blood cell pit counts were performed on 201 subjects, aged 6 months to 90 years, with hemoglobin SC; 43 subjects underwent radionuclide liver-spleen scanning. Pit counts greater than 20% were associated with functional asplenia as assessed by liver-spleen scan, whereas pit counts less than 20% were found in subjects with preserved splenic function. Pit counts greater than 20% were present in 0 of 59 subjects (0%) less than 4 years of age, in 19 of 86 subjects (22%) 4 to 12 years of age, and in 25 of 56 subjects (45%) greater than 12 years of age. Other subjects with hemoglobin SC, who had previously undergone surgical splenectomy, had higher pit counts (59.7% +/- 9.5%) than splenectomized subjects without hemoglobinopathy (38.5% +/- 8.8%) or with sickle cell anemia (20.5% +/- 1.9%; P < .001). Two subjects with hemoglobin SC disease (not splenectomized), ages 14 and 15 years, with pit counts of 40.3% and 41.7% died from pneumococcal septicemia. These data indicate that functional asplenia occurs in many patients with hemoglobin SC disease, but its development is usually delayed until after 4 years of age. The pit count is a reliable measure of splenic function in hemoglobin SC disease, but values indicative of functional asplenia (> 20% in our laboratory) are higher than in other disorders. The routine administration of prophylactic penicillin to infants and young children with hemoglobin SC disease may not be necessary.

Entities:  

Mesh:

Year:  1995        PMID: 7718896

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Humoral immunity in children with biliary atresia splenic malformation syndrome.

Authors:  Rachel M Taylor; Paul Cheeseman; Mark Davenport; Sarah A Tizzard; David Goldblatt; Giorgina Mieli-Vergani; Nedim Hadzic
Journal:  Eur J Pediatr       Date:  2003-05-06       Impact factor: 3.183

Review 2.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 3.  Knowledge insufficient: the management of haemoglobin SC disease.

Authors:  Lydia H Pecker; Beverly A Schaefer; Lori Luchtman-Jones
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 4.  Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.

Authors:  Satheesh Chonat; Charles T Quinn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

Review 6.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

Review 7.  Improving outcomes in children with sickle cell disease: treatment considerations and strategies.

Authors:  Ali Amid; Isaac Odame
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

8.  Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ(+) thalassemia genotypes.

Authors:  Tiffany T Yu; Julie Nelson; Michael B Streiff; Sophie Lanzkron; Rakhi P Naik
Journal:  Thromb Res       Date:  2016-03-02       Impact factor: 3.944

Review 9.  Sickle cell disease in childhood: from newborn screening through transition to adult medical care.

Authors:  Charles T Quinn
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

Review 10.  Sickle cell disease.

Authors:  Martin M Meremikwu; Uduak Okomo
Journal:  BMJ Clin Evid       Date:  2016-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.